Amgen Inc announced their experimental new type of cholesterol-fighting injectable drug evolocumab has been able to meet its primary goal. It registered success by reducing 'bad' LDL cholesterol in patients having a genetic tendency of having high levels of the artery-clogging fat.

Two Alzheimer’s drugs under-development have failed in their clinical trials. Bapineuzumab and Solanezumab, the two drugs, have been unsuccessful in helping those patients suffering with mild to moderate dementia.

The research, published in the Jan. 23 issue of the New England Journal of Medicine, states that two novel drugs failed in improving the cognitive function of patients.

The pharmaceutical company, Bristol-Myers Squibb Co. has informed today that its experiment to test whether a drug used for treating skin cancer can be helpful in treating prostate cancer has not succeed.

Yervoy was the drug being tested by the company. Though, the drug was successful in showing some positive results in the patients, who were suffering from an initial stage of the disease.

Swiss company Roche has suffered a major setback as a drug, which is meant for treating diabetes, has been showing side effects. This is the reason that they are going to stop the development of the drug.

The drug known as aleglitazar has shown side effects in the late stage trial of the drug. It has been found that patients who took the drug in the trial suffered problems in their organs.